中心性浆液性脉络膜视网膜病变的发病机制和治疗进展  

Progress in the Pathogenesis and Treatment of Central Serous Chorioretinopathy

作　　者：高龙洋 孙立新 李玲 

机构地区：[1]南华大学衡阳医学院,湖南 衡阳 [2]中南大学湘雅医学院附属常德医院眼科,湖南 常德

出　　处：《临床个性化医学》2025年第1期463-470,共8页Journal of Clinical Personalized Medicine

摘　　要：中心性浆液性脉络膜视网膜病变(CSC)是临床上常见的眼底疾病之一,好发于中青年男性,属于自限性疾病,主要表现为后极部视网膜类圆形视网膜神经上皮下积液。急性中心性浆液性脉络膜视网膜病变(aCSC)患者大多能自愈,视力恢复良好。而慢性中心性浆液性脉络膜视网膜病变(cCSC)患者预后较差,部分继发脉络膜新生血管。目前CSC的具体发病机制仍不明确。对于CSC的治疗也未达成共识,目前有光动力疗法、传统氩激光光凝、微脉冲激光以及药物等多种方法用于临床。本文主要综合分析中心性浆液性脉络膜视网膜病变的发病机制和治疗进展。Central serous chorioretinopathy (CSC) is one of the commom fundus diseases in clinical practice. CSC usually occurs in the young and middle-aged men. It is a self-limited disease, mainly manifested as round retinal subepithelial fluid accumulation in the posterior polar retina. Most patients with acute central serous chorioretinopathy (aCSC) can heal themselves and their visual acuity recovers well. However, patients with chronic central serous chorioretinopathy(cCSC) have a poor prognosis, and some of them have secondary choroidal neovascularization. At present, the specific pathogenesis of CSC is still unclear. There is no consensus on the treatment of csc. Currently, there are many clinical methods such as photodynamic therapy, traditional argon laser photocoagulation, micropulse laser and drugs. This article is comprehensive analysis of the pathogenesis and treatment progress of central serous chorioretinopathy.

关 键 词：中心性浆液性脉络膜视网膜病变 微脉冲激光 药物 

分 类 号：R73[医药卫生—肿瘤]